Stapled Peptide Inhibitors of Autophagy Adapter LC3B

Chembiochem. 2020 Oct 1;21(19):2777-2785. doi: 10.1002/cbic.202000212. Epub 2020 Jun 22.

Abstract

A growing body of evidence suggests that autophagy inhibition enhances the effectiveness of chemotherapy, especially in difficult-to-treat cancers. Existing autophagy inhibitors are primarily lysosomotropic agents. More specific autophagy inhibitors are highly sought-after. The microtubule-associated protein 1A/1B light chain 3B protein, LC3B, is an adapter protein that mediates key protein-protein interactions at several points in autophagy pathways. In this work, we used a known peptide ligand as a starting point to develop improved LC3B inhibitors. We obtained structure-activity relationships that quantify the binding contributions of peptide termini, individual charged residues, and hydrophobic interactions. Based on these data, we used artificial amino acids and diversity-oriented stapling to improve affinity and resistance to biological degradation, while maintaining or improving LC3B affinity and selectivity. These peptides represent the highest-affinity LC3B-selective ligands reported to date, and they will be useful tools for further elucidation of LC3B's role in autophagy and in cancer.

Keywords: LC3B; autophagy; cancer; protein-protein interactions; stapled peptides.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Amino Acids / chemistry
  • Amino Acids / pharmacology
  • Autophagy / drug effects
  • Dose-Response Relationship, Drug
  • Fluorescence Polarization
  • HeLa Cells
  • Humans
  • Ligands
  • Microtubule-Associated Proteins / antagonists & inhibitors*
  • Microtubule-Associated Proteins / metabolism
  • Peptides / chemical synthesis
  • Peptides / chemistry
  • Peptides / pharmacology*
  • Structure-Activity Relationship

Substances

  • Amino Acids
  • Ligands
  • MAP1LC3B protein, human
  • Microtubule-Associated Proteins
  • Peptides